in the target population were observed throughout the clinical development plan conducted abroad.
With repeated dosing, the incidence of TEAEs at each cycle did not suggest any accumulation of toxicity and the safety profile of the FDC was maintained throughout multiple cycle exposure.
Overall, the System Organ Class for which Treatment Emergent Adverse Events (TEAEs) were most commonly reported included the body systems that are most often involved with the cytotoxic effects of chemotherapy administration. Across the treatment groups, TEAEs were most commonly reported in the SOCs of skin and subcutaneous tissue disorders; blood and lymphatic system disorders; general disorders and administration site conditions); and GI disorders.